253 409

Cited 3 times in

유방암 조직에서 ATP를 이용한 항암제 반응성 검사의 유용성

Other Titles
 Heterogeneous Chemosensitivity of Breast Cancer Determined by Adeonsine Triphosphate Based Chemotherapy Response Assay 
 최석경  ;  정준  ;  이승아  ;  황승현  ;  안성귀  ;  정우희  ;  이희대 
 JOURNAL OF BREAST CANCER, Vol.13(2) : 180-186, 2010 
Journal Title
Issue Date
Adenosine Triphosphate ; Breast neoplasms ; Drug screening assay
PURPOSE: Breast cancer is heterogeneous disease and the response to chemotherapeutic agents is also heterogeneous from patient to patient. Chemotherapy response assay is in vitro test that is performed to evaluate the degree of tumor growth inhibition by chemotherapy drugs. In this study, we performed the chemotherapy response assay using adenosine triphosphate (ATP-CRA) in breast cancer patients and assessed the clinical availability. METHODS: Sixty five breast cancer patients were enrolled in this study. Cancer cells were evenly divided and treated with commonly used chemotherapeutic drugs in breast cancer (doxorubicin, epirubicin, 5-fluorouracil, paclitaxel, docetaxel, vinorelbine, and gemcitabine). To verify in vitro ATP-CRA indirectly, we analyzed the correlation between cell death rate (CDR) of doxorubicin and epirubicin, and between doxorubicin and paclitaxel. We also analyzed the mean CDR of doxorubicin, epirubicin and paclitaxel by HER2 status. RESULTS: We could successfully perform the ATP-CRA in 60 patients (95.2%). In all cases, we can get the results within 7 days. The range of CDR was very wide, from 0 to more than 50%, except gemcitabine. Epirubicin showed the highest mean CDR (39.9%) and doxorubicin, paclitaxel in order. According to the chemosensitivity index, paclitaxel is the most frequently first-ranked and doxorubicin, epirubicin in order. Correlation coefficient between the cell death rate of doxorubicin and epirubicin is 0.4210 and 0.1299 between paclitaxel and doxorubicin. In HER2 positive group, mean CDR of paclitaxel, epirubicin and doxorubicin was higher than in HER2 negative group, even though epirubicin and doxorubicin were not statistically significant (p=0.018, p=0.114, p=0.311, respectively). CONCLUSION: ATP-CRA showed heterogeneous results in individual patients. ATP-CRA was successful and can be performed within short time period. According to our in vitro study, it showed similar results with in vivo study but for the clinical use, the prospective randomized controlled trial should be preceded
Files in This Item:
T201002951.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
Yonsei Authors
Ahn, Sung Gwe(안성귀) ORCID logo https://orcid.org/0000-0002-8778-9686
Lee, Seung Ah(이승아)
Lee, Hy De(이희대)
Jung, Woo Hee(정우희)
Jeong, Joon(정준) ORCID logo https://orcid.org/0000-0003-0397-0005
Choi, Suk Kyung(최석경)
Hwang, Seung Hyun(황승현)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.